Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 9, 2026, 10:31 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2569–2592 of 2,912 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Control Capsules Clear all

Conditions: Schizophrenia, Schizoaffective Disorder, Alcohol Dependence, Nicotine Dependence
Interventions: Varenicline, Placebo; Drug
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 69 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Psoriatic Plaque
Interventions: KBL697; Drug
Lead sponsor: KoBioLabs; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 6
States / cities: Birmingham, Alabama • Santa Ana, California • Santa Monica, California + 3 more

Conditions: Plaque Psoriasis
Interventions: (CP-6890,550) Tofacitinib, Placebo, (CP-690,550) Tofacitinib; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013
U.S. locations: 5
States / cities: Los Angeles, California • Tampa, Florida • Dallas, Texas + 1 more

Conditions: Radiation Injuries
Interventions: Pendulum Glucose Control (PGC); Biological
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Major Depressive Disorder
Interventions: Lumateperone, Placebo; Drug
Lead sponsor: Intra-Cellular Therapies, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 485 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 15
States / cities: Phoenix, Arizona • Glendale, California • Oceanside, California + 12 more

Conditions: Solid Tumor
Interventions: 7HP349 Single Ascending Dose, 7HP349 Multiple Ascending Dose, Placebo Single Ascending Dose, Placebo Multiple Ascending Dose, 7HP349 Food Effect; Drug
Lead sponsor: 7 Hills Pharma, LLC; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Secaucus, New Jersey

Conditions: Clostridium Difficile Infection Recurrence
Interventions: Bacillus velezensis DSM 33864, Placebo; Dietary Supplement
Lead sponsor: Novozymes A/S; Industry
Eligibility: 18 Years and older
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Royal Oak, Michigan

Conditions: Urinary Tract Infections
Interventions: Uqora, Group1, Group 2; Dietary Supplement
Lead sponsor: Hawthorne Effect Inc.; Other
Eligibility: 18 Years and older · Female only
Enrollment: 360 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: San Diego, California

Conditions: Growth Hormone Deficiency (GHD)
Interventions: LUM-201, Matched Placebo (Capsules); Drug · Other
Lead sponsor: Lumos Pharma; Industry
Eligibility: 3 Years to 11 Years
Enrollment: 150 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 31
States / cities: Birmingham, Alabama • Madera, California • Orange, California + 28 more

Conditions: Moderate-severe Pain
Interventions: ALO-02; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 7 Years to 17 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 16
States / cities: Lancaster, California • Los Angeles, California • Sacramento, California + 4 more

Conditions: Postmenopausal Osteoporosis, Gut Microbiota, Cardiovascular Diseases
Interventions: blackcurrant (BC) extract; Drug
Lead sponsor: University of Connecticut; Other
Eligibility: 45 Years to 60 Years · Female only
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Storrs, Connecticut

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Hypericum perforatum, Placebo; Drug · Other
Lead sponsor: National Center for Complementary and Integrative Health (NCCIH); NIH
Eligibility: 6 Years to 17 Years
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 1
States / cities: Kenmore, Washington

Conditions: Alzheimer's Disease
Interventions: BMS-708163, Placebo; Drug
Lead sponsor: Bristol-Myers Squibb; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010
U.S. locations: 3
States / cities: Cypress, California • Glendale, California • Eatontown, New Jersey

Conditions: Bipolar Disorder, Bipolar Depression
Interventions: N-acetylcysteine, Minocycline, Placebo; Dietary Supplement · Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Headache, Migraine, Migraine, Migraine Disorders, Headache
Interventions: Cognitive Behavioral Therapy (CBT), Placebo, Amitriptyline, Biofeedback-Assisted Relaxation Training (BART), Cognitive Reappraisal Training (CR); Behavioral · Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 10 Years to 17 Years
Enrollment: 132 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Healthy
Interventions: PF-05175157, Placebo; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 40 Years
Enrollment: 12 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Alzheimers Disease
Interventions: CNP520 50mg, CNP520 15mg, Matching placebo; Drug · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 60 Years to 75 Years
Enrollment: 1,145 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2017 – 2020
U.S. locations: 95
States / cities: Phoenix, Arizona • Sun City, Arizona • Tucson, Arizona + 83 more

Conditions: Psoriasis
Interventions: Placebo, VTP-43742; Drug
Lead sponsor: Vitae Pharmaceuticals Inc., an Allergan affiliate; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Fair Lawn, New Jersey

Conditions: Solid Tumours
Interventions: Selumetinib, Moxifloxacin, selumetinib placebo; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 45 Years · Male only
Enrollment: 54 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Cognitive Impairment Associated With Schizophrenia (CIAS), Cognitive Impairment, Schizophrenia
Interventions: RL-007 (Inidascamine), Placebo; Drug
Lead sponsor: Recognify Life Sciences; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 242 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 20
States / cities: Culver City, California • Garden Grove, California • Lafayette, California + 17 more

Conditions: Parkinson's Disease
Interventions: Trans-Resveratrol; Drug
Lead sponsor: Georgetown University; Other
Eligibility: 55 Years to 85 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Generalized Anxiety Disorder
Interventions: Vortioxetine, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years and older
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 33
States / cities: Anaheim, California • Arcadia, California • Irvine, California + 30 more

Conditions: Plaque Psoriasis
Interventions: AGN-242428, Placebo; Drug
Lead sponsor: Vitae Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 15
States / cities: Birmingham, Alabama • Tucson, Arizona • Fort Smith, Arkansas + 12 more

Conditions: Chronic Idiopathic Constipation
Interventions: YKP10811, Placebo; Drug
Lead sponsor: SK Life Science, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 334 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 69
States / cities: Birmingham, Alabama • Chandler, Arizona • Phoenix, Arizona + 58 more

Search by objective public record fields.

Varenicline Treatment in Alcohol and Nicotine Dependent Patients With Schizophrenia

A Study to Investigate Efficacy and Safety of KBL697 in Patients with Moderate Plaque Type Psoriasis

Study Of The Mechanism Of Action Of CP-690,550 In The Skin Of Subjects With Moderate To Severe Chronic Plaque Psoriasis

Oral 5 Strain Probiotic for GI Toxicity Mitigation During Pelvic Radiation

Clinical Trial of Lumateperone as Adjunctive Therapy in the Treatment of Patients With Major Depressive Disorder

A Phase 1 SAD and MAD Study of the Safety, Tolerability and PK of 7HP349 in Normal Healthy Male Subjects

Bacillus Velezensis DSM 33864 for Reduction of the Risk of Recurrent Clostridioides Difficile Infections

Uqora Supplements in Women With UTIs

Phase 3 Study of LUM-201 in Children With Growth Hormone Deficiency

Safety and Pharmacokinetic Study of ALO-02 in Children Ages 7-17 With Pain

Blackcurrants Modify Gut Microbiota and Reduce Osteoporosis and CVD Risk

Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD)

Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BMS-708163

A Pilot Study Investigating the Efficacy of Minocycline and N-Acetyl Cysteine for Bipolar Depression

Mind and Body Approaches to Pain Reduction in Youth With Migraine

Effect Of Single-Dose PF-05175157 On Metabolic And Cardiopulmonary Parameters

A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease

An Ascending Multiple Dose Study With VTP-43742 in Healthy Volunteers

To Assess the Effects of Single Oral Dose of Selumetinib [AZD6244; ARRY-142886] [Hyd-Sulfate]), on QTc Interval in Healthy Male Volunteers

A Study to Evaluate RL-007 in the Treatment of Cognitive Impairment Associated With Schizophrenia (CIAS)

RESvEraTrol in Parkinson's Disease (RESET)

An Efficacy and Safety Study of Vortioxetine (Lu AA21004) in Treating Generalized Anxiety Disorder

AGN-242428 in the Treatment of Plaque Psoriasis

A Multicenter, Double-Blind, Randomized, Placebo-Controlled, 12-Week, Dose-Range-Finding Trial of YKP10811 Capsules Administered Once Daily to Subjects With Chronic Idiopathic Constipation